Aequus Pharmaceuticals Inc (AQS) - Total Liabilities

Latest as of September 2025: CA$7.09 Million CAD ≈ $5.13 Million USD

Based on the latest financial reports, Aequus Pharmaceuticals Inc (AQS) has total liabilities worth CA$7.09 Million CAD (≈ $5.13 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore AQS year-over-year net asset growth to track the company's year-over-year net asset growth rate.

Aequus Pharmaceuticals Inc - Total Liabilities Trend (2013–2024)

This chart illustrates how Aequus Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See AQS FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Aequus Pharmaceuticals Inc Competitors by Total Liabilities

The table below lists competitors of Aequus Pharmaceuticals Inc ranked by their total liabilities.

Company	Country	Total Liabilities
CENTAURUS ENERGY INC. F:72M0	Germany	€5.59 Million
Craven House Capital PLC LSE:CRV	UK	$1.93 Million
Revolution Beauty Group PLC LSE:REVB	UK	GBX105.86 Million
Foncière 7 investissement Société Anonyme PA:LEBL	France	€57.45K
Digital 9 Infrastructure PLC LSE:DGI9	UK	GBX4.39 Million
Helium One Global Ltd LSE:HE1	UK	GBX1.26 Million
Zapp Electric Vehicles Group Limited Ordinary Shares NASDAQ:ZAPP	USA	$27.91 Million
Vicarious Surgical Inc. NYSE:RBOT	USA	$15.26 Million

Liability Composition Analysis (2013–2024)

This chart breaks down Aequus Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AQS market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.03	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-1.03	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	36.14	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Aequus Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Aequus Pharmaceuticals Inc (2013–2024)

The table below shows the annual total liabilities of Aequus Pharmaceuticals Inc from 2013 to 2024.

Year	Total Liabilities	Change
2024-12-31	CA$7.26 Million ≈ $5.25 Million	+34.85%
2023-12-31	CA$5.38 Million ≈ $3.89 Million	+75.16%
2022-12-31	CA$3.07 Million ≈ $2.22 Million	+20.03%
2021-12-31	CA$2.56 Million ≈ $1.85 Million	-0.07%
2020-12-31	CA$2.56 Million ≈ $1.85 Million	+0.43%
2019-12-31	CA$2.55 Million ≈ $1.84 Million	+709.71%
2018-12-31	CA$314.90K ≈ $227.79K	-14.16%
2017-12-31	CA$366.84K ≈ $265.36K	-50.72%
2016-12-31	CA$744.41K ≈ $538.50K	-34.99%
2015-12-31	CA$1.15 Million ≈ $828.33K	+53.80%
2014-12-31	CA$744.51K ≈ $538.56K	+1212.23%
2013-12-31	CA$56.74K ≈ $41.04K	--

About Aequus Pharmaceuticals Inc

V:AQS Canada Drug Manufacturers - Specialty & Generic

Market Cap

$479.73K

CA$663.17K CAD

Market Cap Rank

#30936 Global

#1646 in Canada

Share Price

CA$0.01

Change (1 day)

+0.00%

52-Week Range

CA$0.01 - CA$0.01

All Time High

CA$0.69